Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension

References

• Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.43(12 Suppl. S), 5S–12S (2004).
   PubMed Web of Science ®Google Scholar
• Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest100(5), 1268–1271 (1991).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Krowka MJ, Strassburg C. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet363(9419), 1461–1468 (2004)
   PubMed Web of Science ®Google Scholar
• Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis.62(11), 1088–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111(23), 3105–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Frank H, Humbert M, Jais X et al. The effect of anticoagulant therapy in primary and anorectic drug- induced pulmonary hypertension. Chest112(3), 714–721 (1997).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J.25(2), 244–249 (2005).
   PubMed Web of Science ®Google Scholar
• Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-b receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nature Genet.26(1), 81–84 (2000).
   PubMed Web of Science ®Google Scholar
• Deng Z, Haghighi F, Helleby L et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am. J. Respir.Crit. Care Med.161(3 Pt 1), 1055–1059 (2000).
   Google Scholar
• Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-b family. J. Med. Genet.37(10), 741–745 (2000).
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.333(4), 214–221 (1995).
   PubMed Web of Science ®Google Scholar
• McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am. J. Physiol.267(5 Pt 2), H1921–H1927 (1994).
   PubMed Web of Science ®Google Scholar
• Mason NA, Springall DR, Burke M et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J. Pathol.185(3), 313–318 (1998).
   PubMed Web of Science ®Google Scholar
• Lin CS. Tissue expression, distribution, and regulation of PDE5. Int. J. Impot. Res.16(Suppl 1), S8–S10 (2004).
   PubMed Web of Science ®Google Scholar
• Wright LC, Seybold J, Robichaud A, Adcock IM, Barnes PJ. Phosphodiesterase expression in human epithelial cells. Am. J. Physiol. Lung. Cell. Mol. Physiol.275(4), L694–L700 (1998).
   PubMedGoogle Scholar
• Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med.338(20), 1397–1404 (1998).
   PubMed Web of Science ®Google Scholar
• Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N. Engl. J. Med.343(18), 1342 (2000).
   PubMed Web of Science ®Google Scholar
• Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am. J. Physiol. Lung. Cell. Mol. Physiol.275(5), L931–L941 (1998).
   PubMed Web of Science ®Google Scholar
• Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am. J. Physiol. Lung. Cell. Mol. Physiol.281(5), L1051–L1057 (2001).
   PubMed Web of Science ®Google Scholar
• Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol.35(10), 1743–1751 (1986).
   PubMed Web of Science ®Google Scholar
• Souness JE, Brazdil R, Diocee BK, Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br. J. Pharmacol.98(3), 725–734 (1989).
   PubMed Web of Science ®Google Scholar
• Griffith TM, Edwards DH, Lewis MJ, Henderson AH. Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation. Eur. J. Pharmacol.112(2), 195–202 (1985).
   Google Scholar
• Martin W, Furchgott RF, Villani GM, Jothianandan D. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J. Pharmacol. Exp. Ther.237(2), 539–547 (1986).
   PubMed Web of Science ®Google Scholar
• Schoeffter P, Lugnier C, Demesy-Waeldele F, Stoclet JC. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem. Pharmacol.36(22), 3965–3972 (1987).
   Google Scholar
• Popescu LM, Panoiu C, Hinescum C, Nutu O. The mechanism of cGMP-induced relaxation in vascular smooth muscle. Eur. J. Pharmacol.107(3), 393–394 (1985).
   PubMed Web of Science ®Google Scholar
• Braner DA, Panoiu C, Hinescu M, Nutu O. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. Heart Circ. Physiol.264(1), H252–H258 (1993).
   Google Scholar
• McMahon TJ, Ignarro LJ, Kadowitz J. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J. Appl. Physiol.74(4), 1704–1711 (1993).
   PubMed Web of Science ®Google Scholar
• Cohen AH, Hanson K, Morris K et al. Inhibition of cyclic 3'-5'- guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest.97(1), 172–179 (1996).
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Raffestin B, Le Monnier de Gouville AC, Adnot S. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br. J. Pharmacol.125(4), 681–688 (1998).
   Google Scholar
• Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br. J. Urol.78(2), 257–61 (1996).
   PubMedGoogle Scholar
• Weimann J, Ullrich R, Hromi J et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology92(6), 1702–12 (2000).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier KP, Ghofrani HA et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med.169(1), 39–45 (2004).
   PubMed Web of Science ®Google Scholar
• Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.Am. J. Respir. Crit. Care Med.165(8), 1098–1102 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao L, Mason NA, Morrell NW et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation104(4), 424–428 (2001).
   PubMed Web of Science ®Google Scholar
• Itoh T, Nagaya N, Fujii T et al. A Combination of Oral Sildenafil and Beraprost Ameliorates Pulmonary Hypertension in Rats. Am. J. Respir. Crit. Care Med.169(1), 34–38 (2004).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Nagaya N, Fujii T et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol.44(7), 1488–1496 (2004).
   PubMed Web of Science ®Google Scholar
• Sauzeau V, Rolli-Derkinderen M, Lehoux S et al. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ. Res.93(7), 630–637 (2003).
   Google Scholar
• Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation104(11), 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation105(20), 2398–2403 (2002).
   PubMed Web of Science ®Google Scholar
• Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir. Med.99(12), 1501–1510 (2005).
   Google Scholar
• Lepore JJ, Maroo A, Bigatello LM et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest127(5), 1647–1653 (2005).
   PubMed Web of Science ®Google Scholar
• Alaeddini J, Uber PA, Park MH, Scott RL, Ventura HO, Mehra MR. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am. J. Cardiol.94(11), 1475–1477 (2004).
   PubMed Web of Science ®Google Scholar
• Trachte AL, Lobato EB, Urdaneta F et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann. Thorac. Surg.79(1), 194–197 (2005).
   Google Scholar
• Sheth A, Park JE, Ong YE, Ho TB, Madden BP. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vasc. Pharmacol.42(2), 41–45 (2005).
   PubMedGoogle Scholar
• Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol.43(7), 1149–1153 (2004).
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353(20), 2148–57 (2005).
   PubMed Web of Science ®Google Scholar
• Pfizer Revatio, package insert. 1–13 (2005).
   Google Scholar
• Wilkins MR, Paul GA, Strange JW et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med.171(11), 1292–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J. Heart Lung Transplant.24(4), 498–500 (2005).
   Google Scholar
• Machado RF, Martyr S, Kato GJ et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol.130(3), 445–453 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandes CJ, Martyr S, Kato GJ et al. Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. J. Inherit. Metab. Dis.28(4), 603–605 (2005).
   Google Scholar
• Castro O, Gladwin MT, Kopterides P, Fremont R, Medoff BD. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med.350(9), 886–895 (2004).
   Google Scholar
• Derchi G, Forni GL, Formisano F et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica90(4), 452–458 (2005).
   PubMed Web of Science ®Google Scholar
• Hon KL, Cheung KL, Siu KL et al. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol. Neonate.88(2), 109–112 (2005).
   PubMedGoogle Scholar
• Juliana A, Abbad F. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur. J. Pediatr.164(10), 626–629 (2005).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J.24(6), 1007–1010 (2004).
   PubMed Web of Science ®Google Scholar
• Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin.Pharmacol.60(1), 107–112 (2005).
   PubMed Web of Science ®Google Scholar
• Ikeda D, Tsujino I, Ohira H et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J. Cardiovasc. Pharmacol.45(4), 286–289 (2005).
   Google Scholar
• Okyay K, Cemri M, Boyac B, Yalcn R, Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome. Cardiol. Rev.13(6), 312–314 (2005).
   PubMedGoogle Scholar
• Kataoka M, Satoh T, Manabe T et al. Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol. Intern. Med.43(10), 945–950 (2004).
   Google Scholar
• Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am. J. Cardiol.96(9), 1334–1336 (2005).
   PubMed Web of Science ®Google Scholar
• Kataoka M, Satoh T, Manabe T et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ. J.69(4), 461–465 (2005).
   Google Scholar
• Angel Gomez-Sanchez M, Saenz De La Calzada C, Escribano Subias P et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur. J. Heart Fail.6(5), 615–617 (2004).
   Google Scholar
• Gomez-Moreno S, Lage E, Hernandez A et al. Use of oral sildenafil in patients with irreversible pulmonary hypertension not eligible for heart transplantation. Transplantation Proc.37(3), 1550–1551 (2005).
   Google Scholar
• Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann. Intern. Med.139(10), 871–873 (2003).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet360(9337), 895–900 (2002).
   PubMed Web of Science ®Google Scholar
• Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J.55(1), 55–59 (2003).
   PubMedGoogle Scholar
• Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research1539(1–2), 16–27 (2001).
   PubMed Web of Science ®Google Scholar